Recombinant human fibroblast growth factor and autogenous bone for periodontal regeneration: Alone or in combination? A randomized clinical trial
Kosuke Kojima,Yohei Kamata,Tomoko Shimizu,Satsuki Sato,Sota Suzuki,Yuya Takanashi,Sawako Hojo,Takeshi Yoshino,Shinya Fuchida,Toshiyuki Tamura,Masato Minabe,Toshiro Kodama,Takaomi Kessoku,Shunsuke Oyamada
DOI: https://doi.org/10.1111/jre.13310
2024-06-11
Journal of Periodontal Research
Abstract:Three different periodontal regeneration therapies for intraosseous defects. Aim To compare the outcomes of therapy using recombinant human fibroblast growth factor (rhFGF)‐2 combined with autologous bone grafting (ABG) therapy with those of rhFGF‐2 alone and ABG alone in the treatment of periodontal intraosseous defects. Methods Periodontal intraosseous defects were randomized to receive rhFGF‐2 therapy + ABG, rhFGF‐2 therapy alone, or ABG alone. Periodontal examination and periapical radiography were performed preoperatively and at 3, 6, and 12 months postoperatively. Results At the 12 months follow‐up, all three groups showed significant improvement in the clinical attachment level (CAL): 5.6 ± 1.6, 5.8 ± 1.7, and 5.2 ± 1.6 mm in the rhFGF‐2 + ABG, rhFGF‐2 alone, and ABG alone groups, respectively, with no significant inter‐group differences (p
dentistry, oral surgery & medicine